Celgene Corporation
86 Morris Avenue
Summit,
NJ 07901
Phone: 908-673-9000
Web Site: http://www.celgene.com
| Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States. Its lead products include THALOMID for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum, an inflammatory complication of leprosy. The company's products also include REVLIMID for the treatment of patients with transfusion-dependent anemia; FOCALIN for attention deficit hyperactivity disorder in children and adolescents; and ALKERAN for the treatment of hematological diseases. Its products in pipeline primarily include CC-10004, a Phase II clinical trial product for psoriasis and psoriatic arthritis; CC-11050, a Phase I trial product for the treatment of inflammatory diseases; and CC-10015, CC-13097, and CC-15965, the pre-clinical stage products for the treatment of inflammatory diseases. The company's products also include anti-proliferatives drugs, which include CC-8490, a Phase I trial completed product; and CC-0227113, Ligase Inhibitor, and PDA-001, the preclinical stage products for the treatment of cancer; kinase inhibitors that include JNK 401, a Phase I/II trial product for the treatment of myelogenous leukemia; and JNK 930, a preclinical stage product for the treatment of fibrotic diseases. Celgene Corporation through supply and distribution agreement with GlaxoSmithKline distributes and sells ALKERAN drug products. It has collaborative agreements with Novartis Pharma AG; and strategic partnership agreement with Pharmion Corporation. The company was founded in 1980 and is headquartered in Summit, New Jersey. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Dr. Sol J. Barer Ph.D., 61
Exec. Chairman, Chief Exec. Officer and Chairman of Exec. Committee
|
$
2.68M |
$
43.23M |
Mr. Robert J. Hugin , 53
Pres, Chief Operating Officer, Sec.
|
$
2.08M |
$
19.63M |
Mr. David W. Gryska , 51
Chief Financial Officer, Chief Accounting Officer and Sr. VP
|
$
32.00K |
N/A |
Mr. Aart Brouwer , 67
Pres of International
|
$
835.00K |
N/A |
Mr. Thomas O. Daniel M.D.,
Pres of Celgene Research
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
